Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients

Julie Ho, Atul Sharma, Kristine Kroeker, Robert Carroll, Sacha De Serres, Ian W Gibson, Patricia Hirt-Minkowski, Anthony Jevnikar, S Joseph Kim, Greg Knoll, David N Rush, Chris Wiebe, Peter Nickerson, Julie Ho, Atul Sharma, Kristine Kroeker, Robert Carroll, Sacha De Serres, Ian W Gibson, Patricia Hirt-Minkowski, Anthony Jevnikar, S Joseph Kim, Greg Knoll, David N Rush, Chris Wiebe, Peter Nickerson

Abstract

Introduction: Subclinical inflammation is an important predictor of death-censored graft loss, and its treatment has been shown to improve graft outcomes. Urine CXCL10 outperforms standard post-transplant surveillance in observational studies, by detecting subclinical rejection and early clinical rejection before graft functional decline in kidney transplant recipients.

Methods and analysis: This is a phase ii/iii multicentre, international randomised controlled parallel group trial to determine if the early treatment of rejection, as detected by urine CXCL10, will improve kidney allograft outcomes. Incident adult kidney transplant patients (n~420) will be enrolled to undergo routine urine CXCL10 monitoring postkidney transplant. Patients at high risk of rejection, defined as confirmed elevated urine CXCL10 level, will be randomised 1:1 stratified by centre (n=250). The intervention arm (n=125) will undergo a study biopsy to check for subclinical rejection and biopsy-proven rejection will be treated per protocol. The control arm (n=125) will undergo routine post-transplant monitoring. The primary outcome at 12 months is a composite of death-censored graft loss, clinical biopsy-proven acute rejection, de novo donor-specific antibody, inflammation in areas of interstitial fibrosis and tubular atrophy (Banff i-IFTA, chronic active T-cell mediated rejection) and subclinical tubulitis on 12-month surveillance biopsy. The secondary outcomes include decline of graft function, microvascular inflammation at 12 months, development of IFTA at 12 months, days from transplantation to clinical biopsy-proven rejection, albuminuria, EuroQol five-dimension five-level instrument, cost-effectiveness analysis of the urine CXCL10 monitoring strategy and the urine CXCL10 kinetics in response to rejection therapy.

Ethics and dissemination: The study has been approved by the University of Manitoba Health Research Ethics Board (HS20861, B2017:076) and the local research ethics boards of participating centres. Recruitment commenced in March 2018 and results are expected to be published in 2023. De-identified data may be shared with other researchers according to international guidelines (International Committee of Medical Journal Editors [ICJME]).

Trial registration number: NCT03206801; Pre-results.

Keywords: biomarker; clinical trial; kidney transplant; subclinical rejection; urine CXCL10.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Trial design of a multicentre randomised controlled trial of urine CXCL10 monitoring postrenal transplant.

References

    1. Wiebe C, Nickerson P. Strategic Use of Epitope Matching to Improve Outcomes. Transplantation 2016;100:2048–52. 10.1097/TP.0000000000001284
    1. Wiebe C, Ho J, Gibson IW, et al. . Carpe diem-Time to transition from empiric to precision medicine in kidney transplantation. Am J Transplant 2018;18:1615–25. 10.1111/ajt.14746
    1. Kirk AD. Clinical tolerance 2008. Transplantation 2009;87:953–5. 10.1097/TP.0b013e31819d415e
    1. Kirk AD, Mannon RB, Swanson SJ, et al. . Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005;18:2–14. 10.1111/j.1432-2277.2004.00019.x
    1. Ho J, Wiebe C, Gibson IW, et al. . Immune monitoring of kidney allografts. Am J Kidney Dis 2012;60:629–40. 10.1053/j.ajkd.2012.01.028
    1. Hirt-Minkowski P, De Serres SA, Ho J. Developing renal allograft surveillance strategies – urinary biomarkers of cellular rejection. Can J Kidney Health Dis 2015;2:61 10.1186/s40697-015-0061-x
    1. Nankivell BJ, Borrows RJ, Fung CL-S, et al. . The natural history of chronic allograft nephropathy. N Engl J Med Overseas Ed 2003;349:2326–33. 10.1056/NEJMoa020009
    1. Nickerson P, Jeffery J, Gough J, et al. . Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998;9:482–7.
    1. Grimm PC, Nickerson P, Gough J, et al. . Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003;14:1662–8. 10.1097/01.ASN.0000066143.02832.5E
    1. Cosio FG, Grande JP, Wadei H, et al. . Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005;5:2464–72. 10.1111/j.1600-6143.2005.01050.x
    1. Cosio FG, El Ters M, Cornell LD, et al. . Changing kidney allograft histology early posttransplant: prognostic implications of 1-year protocol biopsies. Am J Transplant 2016;16:194–203. 10.1111/ajt.13423
    1. Moreso F, Ibernon M, Gomà M, et al. . Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006;6:747–52. 10.1111/j.1600-6143.2005.01230.x
    1. Loupy A, Vernerey D, Tinel C, et al. . Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol 2015;26:1721–31. 10.1681/ASN.2014040399
    1. Szederkényi E, Iványi B, Morvay Z, et al. . Treatment of subclinical injuries detected by protocol biopsy improves the long-term kidney allograft function: a single center prospective randomized clinical trial. Transplant Proc 2011;43:1239–43. 10.1016/j.transproceed.2011.03.078
    1. Rush D, Nickerson P, Gough J, et al. . Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998;9:2129–34.
    1. Kurtkoti J, Sakhuja V, Sud K, et al. . The utility of 1- and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant 2008;8:317–23. 10.1111/j.1600-6143.2007.02049.x
    1. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. . Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12:1157–67. 10.1111/j.1600-6143.2012.04013.x
    1. Kanmaz T, Feng P, Torrealba J, et al. . Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation 2004;78:1002–7. 10.1097/01.TP.0000134397.55564.71
    1. Tatapudi RR, Muthukumar T, Dadhania D, et al. . Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004;65:2390–7. 10.1111/j.1523-1755.2004.00663.x
    1. Hricik DE, Nickerson P, Formica RN, et al. . Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013;13:2634–44. 10.1111/ajt.12426
    1. Schaub S, Nickerson P, Rush D, et al. . Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009;9:1347–53. 10.1111/j.1600-6143.2009.02645.x
    1. Hu H, Aizenstein BD, Puchalski A, et al. . Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004;4:432–7. 10.1111/j.1600-6143.2004.00354.x
    1. Hu H, Kwun J, Aizenstein BD, et al. . Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009;87:1814–20. 10.1097/TP.0b013e3181a66b3e
    1. Hauser IA, Spiegler S, Kiss E, et al. . Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005;16:1849–58. 10.1681/ASN.2004100836
    1. Jackson JA, Kim EJ, Begley B, et al. . Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011;11:2228–34. 10.1111/j.1600-6143.2011.03680.x
    1. Peng W, Chen J, Jiang Y, et al. . Urinary fractalkine is a marker of acute rejection. Kidney Int 2008;74:1454–60. 10.1038/ki.2008.459
    1. Rabant M, Amrouche L, Lebreton X, et al. . Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol 2015;26:2840–51. 10.1681/ASN.2014080797
    1. Hirt-Minkowski P, Amico P, Ho J, et al. . Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant 2012;12:1811–23. 10.1111/j.1600-6143.2012.03999.x
    1. Ho J, Rush DN, Karpinski M, et al. . Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 2011;92:878–82. 10.1097/TP.0b013e31822d4de1
    1. Blydt-Hansen TD, Gibson IW, Gao A, et al. . Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. Transplantation 2015;99:797–804. 10.1097/TP.0000000000000419
    1. Suthanthiran M, Schwartz JE, Ding R, et al. . Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med Overseas Ed 2013;369:20–31. 10.1056/NEJMoa1215555
    1. Matz M, Beyer J, Wunsch D, et al. . Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006;69:1683–90. 10.1038/sj.ki.5000343
    1. Ho J, Schaub S, Wiebe C, et al. . Urinary CXCL10 chemokine is associated with alloimmune and virus compartment-specific renal allograft inflammation. Transplantation 2018;102:521–9.
    1. Ho J, Rush DN, Gibson IW, et al. . Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010;90:394–400. 10.1097/TP.0b013e3181e6424d
    1. Hirt-Minkowski P, Ho J, Gao A, et al. . Prediction of long-term renal allograft outcome by early urinary CXCL10 chemokine levels. Transplant Direct 2015;1:1 10.1097/TXD.0000000000000537
    1. Hirt-Minkowski P, Rush DN, Gao A, et al. . Six-month urinary CCL2 and CXCL10 levels predict long-term renal allograft outcome. Transplantation 2016;100:1988–96. 10.1097/TP.0000000000001304
    1. Haas M, Loupy A, Lefaucheur C, et al. . The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018;18:293–307. 10.1111/ajt.14625
    1. Kotton CN, Kumar D, Caliendo AM, et al. . The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2018;102:900–31. 10.1097/TP.0000000000002191
    1. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. . Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015;15:2921–30. 10.1111/ajt.13347
    1. Wiebe C, Nevins TE, Robiner WN, et al. . The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant 2015;15:2197–202. 10.1111/ajt.13341
    1. Park WD, Griffin MD, Cornell LD, et al. . Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010;21:1987–97. 10.1681/ASN.2010010049
    1. Gago M, Cornell LD, Kremers WK, et al. . Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012;12:1199–207. 10.1111/j.1600-6143.2011.03911.x
    1. García-Carro C, Dörje C, Åsberg A, et al. . Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. Transplantation 2017;101:1410–5. 10.1097/TP.0000000000001216
    1. Mannon RB, Matas AJ, Grande J, et al. . Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010;10:2066–73. 10.1111/j.1600-6143.2010.03240.x
    1. Nankivell BJ, Shingde M, Keung KL, et al. . The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 2018;18:364–76. 10.1111/ajt.14609
    1. Lefaucheur C, Gosset C, Rabant M, et al. . T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant 2018;18:377–90. 10.1111/ajt.14565
    1. Mengel M, Reeve J, Bunnag S, et al. . Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009;9:1859–67. 10.1111/j.1600-6143.2009.02727.x
    1. Matas AJ, Leduc R, Rush D, et al. . Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010;10:315–23. 10.1111/j.1600-6143.2009.02943.x
    1. Shishido S, Asanuma H, Nakai H, et al. . The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003;14:1046–52. 10.1097/01.ASN.0000056189.02819.32
    1. Heilman RL, Devarapalli Y, Chakkera HA, et al. . Impact of Subclinical Inflammation on the Development of Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients. Am J Transplant 2010;10:563–70. 10.1111/j.1600-6143.2009.02966.x
    1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450–62. 10.1111/j.1600-6143.2010.03283.x
    1. Devos JM, Gaber AO, Teeter LD, et al. . Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection. Transplantation 2014;97:534–40. 10.1097/01.TP.0000438196.30790.66
    1. Everly MJ, Rebellato LM, Haisch CE, et al. . Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013;95:410–7. 10.1097/TP.0b013e31827d62e3
    1. Heilman RL, Nijim A, Desmarteau YM, et al. . De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation 2014;98:1310–5. 10.1097/TP.0000000000000216
    1. Cooper JE, Gralla J, Adebiyi O, et al. . Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Clin Transpl 2013:407–12.
    1. Ho J, Wiebe C, Gibson IW, et al. . Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation 2014;98:39–46. 10.1097/01.TP.0000442776.40295.73
    1. Mevik BH, Liland KH. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
    1. Groenwold RHH, Donders ART, Roes KCB, et al. . Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol 2012;175:210–7. 10.1093/aje/kwr302
    1. Groenwold RH, Moons KG, Vandenbroucke JP. Randomized trials with missing outcome data: how to analyze and what to report. CMAJ 2014;186:1153–7. 10.1503/cmaj.131353
    1. Little RJ, D’Agostino R, Cohen ML, et al. . The prevention and treatment of missing data in clinical trials. N Engl J Med Overseas Ed 2012;367:1355–60. 10.1056/NEJMsr1203730
    1. Leffondre K, Boucquemont J, Tripepi G, et al. . Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrol Dial Transplant 2015;30:1237–43. 10.1093/ndt/gfu320
    1. Nevins TE, Robiner WN, Thomas W. Predictive patterns of early medication adherence in renal transplantation. Transplantation 2014;98:878–84. 10.1097/TP.0000000000000148
    1. Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009;87:711–8. 10.1097/TP.0b013e318195c3d5
    1. Howell M, Tong A, Wong G, et al. . Important outcomes for kidney transplant recipients: a nominal group and qualitative study. Am J Kidney Dis 2012;60:186–96. 10.1053/j.ajkd.2012.02.339
    1. Tong A, Crowe S, Chando S, et al. . Research Priorities in CKD: Report of a National Workshop Conducted in Australia. Am J Kidney Dis 2015;66:212–22. 10.1053/j.ajkd.2015.02.341
    1. Tong A, Gill J, Budde K, et al. . Toward establishing core outcome domains for trials in kidney transplantation: report of the standardized outcomes in nephrology-kidney transplantation consensus workshops. Transplantation 2017;101:1887–96. 10.1097/TP.0000000000001774

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する